Start-up Percutaneous “Access-and-Closure” System Company Shows Up At ACC

“…presentation of our technology among interventional cardiologists at one of the most important scientific meetings of the year boosts our momentumas we move toward our First-in-Human milestone.”

In short

Start-up medical technology company Vasostitch, appeared delighted just to be there, as its technology was featured at the annual scientific meeting of the American College of Cardiology (ACC) this week in Chicago. According to a company press release, VasoStitch is developing a percutaneous access-and-closure system for the non-surgical deployment of large-diameter transcatheter therapeutic devices, such as Transcatheter Aortic Valve Implants (TAVI) and Endovascular Aneurysm Repair (EVAR) devices. The VasoStitch system is designed to reduce procedural complexity and eliminate the need for an “open” surgical procedure.


VasoStitch Inc. is an emerging medical device company that is developing nonsurgical transfemoral and transapical access-and-closure systems to facilitate deployment of large-diameter transcatheter therapeutic devices–designed to reduce procedural complexity and eliminate the need for an “open” surgical procedure.

The challenge with percutaneous catheter-based cardiac procedures is that a surgical cut-down is required for access and then closure. VasoStitch has developed two platform technologies designed to access and close percutaneous therapy sites without the need for open surgery, thus making catheter-based interventions simpler and more accessible.

Company comments

“At this time, surgical means of arterial or cardiac access and closure for large-diameter, catheter-based interventions adds about 60 minutes to a lengthy and complicated procedure. Consequently, a device that can replicate the current ‘gold standard’ of surgical access and repair in a more rapid and facile fashion will reduce healthcare costs dramatically, enhance adoption of large-diameter cardiovascular and endovascular therapies, and improve the efficiency of patient management,” said David W. J. Smith, President and CEO of VasoStitch. “We now look forward to our First-in-Human milestone.”

Regulatory status

VasoStitch’s technologies are not approved for sale in any regulatory jurisdiction. Further, it is not yet available for investigational use or commercial sale in the U.S.

SOURCE: VasoStitch, Market watch, Business Wire